Treatment Biomarkers for ADHD: Taking Stock and Moving Forward

Overview

Journal Transl Psychiatry

Specialties Psychiatry
Public Health

Date 2022 Oct 12

PMID 36224169

Authors

Giorgia Michelini

Luke J Norman

Philip Shaw

Sandra K Loo

Affiliations

Soon will be listed here.

Abstract

The development of treatment biomarkers for psychiatric disorders has been challenging, particularly for heterogeneous neurodevelopmental conditions such as attention-deficit/hyperactivity disorder (ADHD). Promising findings are also rarely translated into clinical practice, especially with regard to treatment decisions and development of novel treatments. Despite this slow progress, the available neuroimaging, electrophysiological (EEG) and genetic literature provides a solid foundation for biomarker discovery. This article gives an updated review of promising treatment biomarkers for ADHD which may enhance personalized medicine and novel treatment development. The available literature points to promising pre-treatment profiles predicting efficacy of various pharmacological and non-pharmacological treatments for ADHD. These candidate predictive biomarkers, particularly those based on low-cost and non-invasive EEG assessments, show promise for the future stratification of patients to specific treatments. Studies with repeated biomarker assessments further show that different treatments produce distinct changes in brain profiles, which track treatment-related clinical improvements. These candidate monitoring/response biomarkers may aid future monitoring of treatment effects and point to mechanistic targets for novel treatments, such as neurotherapies. Nevertheless, existing research does not support any immediate clinical applications of treatment biomarkers for ADHD. Key barriers are the paucity of replications and external validations, the use of small and homogeneous samples of predominantly White children, and practical limitations, including the cost and technical requirements of biomarker assessments and their unknown feasibility and acceptability for people with ADHD. We conclude with a discussion of future directions and methodological changes to promote clinical translation and enhance personalized treatment decisions for diverse groups of individuals with ADHD.

Citing Articles

Advanced machine learning techniques reveal multidimensional EEG abnormalities in children with ADHD: a framework for automatic diagnosis.

Mao Y, Qi X, He L, Wang S, Wang Z, Wang F Front Psychiatry. 2025; 16:1475936.

PMID: 40027598 PMC: 11868104. DOI: 10.3389/fpsyt.2025.1475936.

Infant attention and frontal EEG neuromarkers of childhood ADHD.

Eng C, Patton L, Bell M Dev Cogn Neurosci. 2025; 72:101524.

PMID: 39978291 PMC: 11889623. DOI: 10.1016/j.dcn.2025.101524.

Single-dose methylphenidate induces shift in functional connectivity associated with positive longer term clinical response in adult attention-deficit/hyperactivity disorder.

Pretzsch C, Parlatini V, Murphy D Sci Rep. 2025; 15(1):5794.

PMID: 39962109 PMC: 11833068. DOI: 10.1038/s41598-025-87204-3.

Genome data based deep learning identified new genes predicting pharmacological treatment response of attention deficit hyperactivity disorder.

Zhao Y, Fu Z, Barnett E, Wang N, Zhang K, Gao X Transl Psychiatry. 2025; 15(1):46.

PMID: 39920114 PMC: 11806042. DOI: 10.1038/s41398-025-03250-5.

Decreased impulsiveness and MEG normalization after AI-digital therapy in ADHD children: a RCT.

Bilan D, Chicchi Giglioli I, Cuesta P, Canadas E, de Ramon I, Maestu F Npj Ment Health Res. 2025; 4(1):1.

PMID: 39779908 PMC: 11711623. DOI: 10.1038/s44184-024-00111-9.

References

Milham M, Vogelstein J, Xu T . Removing the Reliability Bottleneck in Functional Magnetic Resonance Imaging Research to Achieve Clinical Utility. JAMA Psychiatry. 2021; 78(6):587-588. DOI: 10.1001/jamapsychiatry.2020.4272. View

Michelini G, Salmastyan G, Vera J, Lenartowicz A . Event-related brain oscillations in attention-deficit/hyperactivity disorder (ADHD): A systematic review and meta-analysis. Int J Psychophysiol. 2022; 174:29-42. DOI: 10.1016/j.ijpsycho.2022.01.014. View

Coghill D, Banaschewski T, Cortese S, Asherson P, Brandeis D, Buitelaar J . The management of ADHD in children and adolescents: bringing evidence to the clinic: perspective from the European ADHD Guidelines Group (EAGG). Eur Child Adolesc Psychiatry. 2021; 32(8):1337-1361. PMC: 8532460. DOI: 10.1007/s00787-021-01871-x. View

Ogrim G, Kropotov J . Predicting Clinical Gains and Side Effects of Stimulant Medication in Pediatric Attention-Deficit/Hyperactivity Disorder by Combining Measures From qEEG and ERPs in a Cued GO/NOGO Task. Clin EEG Neurosci. 2018; 50(1):34-43. PMC: 6291902. DOI: 10.1177/1550059418782328. View

Hermens D, Williams L, Clarke S, Kohn M, Cooper N, Gordon E . Responses to methylphenidate in adolescent AD/HD: evidence from concurrently recorded autonomic (EDA) and central (EEG and ERP) measures. Int J Psychophysiol. 2005; 58(1):21-33. DOI: 10.1016/j.ijpsycho.2005.03.006. View

Lam S, Criaud M, Alegria A, Barker G, Giampietro V, Rubia K . Neurofunctional and behavioural measures associated with fMRI-neurofeedback learning in adolescents with Attention-Deficit/Hyperactivity Disorder. Neuroimage Clin. 2020; 27:102291. PMC: 7287276. DOI: 10.1016/j.nicl.2020.102291. View

Luo X, Guo X, Zhao Q, Zhu Y, Chen Y, Zhang D . A randomized controlled study of remote computerized cognitive, neurofeedback, and combined training in the treatment of children with attention-deficit/hyperactivity disorder. Eur Child Adolesc Psychiatry. 2022; 32(8):1475-1486. PMC: 8857637. DOI: 10.1007/s00787-022-01956-1. View

Clarke A, Barry R, McCarthy R, Selikowitz M, Brown C, Croft R . Effects of stimulant medications on the EEG of children with Attention-Deficit/Hyperactivity Disorder Predominantly Inattentive type. Int J Psychophysiol. 2003; 47(2):129-37. DOI: 10.1016/s0167-8760(02)00119-8. View

Ruan Y, Lin Y, Feng Y, Chen C, Lam M, Guo Z . Improving polygenic prediction in ancestrally diverse populations. Nat Genet. 2022; 54(5):573-580. PMC: 9117455. DOI: 10.1038/s41588-022-01054-7. View

10.

Kowalczyk O, Cubillo A, Smith A, Barrett N, Giampietro V, Brammer M . Methylphenidate and atomoxetine normalise fronto-parietal underactivation during sustained attention in ADHD adolescents. Eur Neuropsychopharmacol. 2019; 29(10):1102-1116. DOI: 10.1016/j.euroneuro.2019.07.139. View

11.

Pereira-Sanchez V, Franco A, Vieira D, de Castro-Manglano P, Soutullo C, Milham M . Systematic Review: Medication Effects on Brain Intrinsic Functional Connectivity in Patients With Attention-Deficit/Hyperactivity Disorder. J Am Acad Child Adolesc Psychiatry. 2020; 60(2):222-235. DOI: 10.1016/j.jaac.2020.10.013. View

12.

Song D, Shin D, Jon D, Ha E . Effects of methylphenidate on quantitative EEG of boys with attention-deficit hyperactivity disorder in continuous performance test. Yonsei Med J. 2005; 46(1):34-41. PMC: 2823055. DOI: 10.3349/ymj.2005.46.1.34. View

13.

Janssen T, Bink M, Gelade K, van Mourik R, Maras A, Oosterlaan J . A randomized controlled trial into the effects of neurofeedback, methylphenidate, and physical activity on EEG power spectra in children with ADHD. J Child Psychol Psychiatry. 2016; 57(5):633-44. DOI: 10.1111/jcpp.12517. View

14.

Peterson B, Potenza M, Wang Z, Zhu H, Martin A, Marsh R . An FMRI study of the effects of psychostimulants on default-mode processing during Stroop task performance in youths with ADHD. Am J Psychiatry. 2009; 166(11):1286-94. PMC: 3289412. DOI: 10.1176/appi.ajp.2009.08050724. View

15.

Kaiser A, Aggensteiner P, Baumeister S, Holz N, Banaschewski T, Brandeis D . Earlier versus later cognitive event-related potentials (ERPs) in attention-deficit/hyperactivity disorder (ADHD): A meta-analysis. Neurosci Biobehav Rev. 2020; 112:117-134. DOI: 10.1016/j.neubiorev.2020.01.019. View

16.

Ethridge P, Weinberg A . Psychometric properties of neural responses to monetary and social rewards across development. Int J Psychophysiol. 2018; 132(Pt B):311-322. DOI: 10.1016/j.ijpsycho.2018.01.011. View

17.

Hong S, Harrison B, Fornito A, Sohn C, Song I, Kim J . Functional dysconnectivity of corticostriatal circuitry and differential response to methylphenidate in youth with attention-deficit/hyperactivity disorder. J Psychiatry Neurosci. 2014; 40(1):46-57. PMC: 4275331. DOI: 10.1503/jpn.130290. View

18.

Krepel N, Egtberts T, Sack A, Heinrich H, Ryan M, Arns M . A multicenter effectiveness trial of QEEG-informed neurofeedback in ADHD: Replication and treatment prediction. Neuroimage Clin. 2020; 28:102399. PMC: 7481574. DOI: 10.1016/j.nicl.2020.102399. View

19.

Elliott M, Knodt A, Hariri A . Striving toward translation: strategies for reliable fMRI measurement. Trends Cogn Sci. 2021; 25(9):776-787. PMC: 8363569. DOI: 10.1016/j.tics.2021.05.008. View

20.

Cortese S . Debate: Are Stimulant Medications for Attention-Deficit/Hyperactivity Disorder Effective in the Long Term?. J Am Acad Child Adolesc Psychiatry. 2019; 58(10):936. DOI: 10.1016/j.jaac.2019.04.029. View